Johnson & Johnson completes its $3.05 billion acquisition of Halda Therapeutics, strengthening its oncology pipeline with RIPTAC technology and expanding targeted cancer therapies.
Cupid has received in-principle approval from its Board of Directors to establish a new FMCG manufacturing facility in the Kingdom of Saudi Arabia (KSA), marking the company’s first manufacturing venture outside India.
Amneal Pharmaceuticals Inc. got an approval from the FDA for two denosumab biosimilars, growing their biosimilar offerings in the US.
The European Commission has approved Sanofi’s Wayrilz (rilzabrutinib), a new (novel) oral Bruton’s tyrosine kinase (BTK) inhibitor, as an additional treatment for patients with Immune Thrombocytopenia
The World Health Organization (WHO) has prequalified two rapid antigen test diagnostics (Ag-RDTs) for SARS-CoV-2 infections. This is historic, as Ag-RDTs are now prequalified for use for the first time.
Bristol Myers Squibb positions India as a growth engine, investing in AI-led pharma commercialization, pipeline expansion, and faster market adoption across oncology and cardiology.
.jpeg "Strides Pharma Slips After USFDA Issues Four Observations")
Strides Pharma shares dip after USFDA issues Form 483 observations at its US facility, though the company says issues are procedural with no supply impact.
Ajanta Pharma partners with Biocon to launch Semaglutide in emerging markets, boosting GLP-1 therapy access, therapeutic leadership, and commercial growth in diabetes care.
Industry leaders share how AI, GCCs, local manufacturing, and quality-first strategies are reshaping India’s life sciences, biometrics, medical devices, and lab solutions ecosystem.
India pharma partnerships in 2025 are accelerating innovation, patient care, digital transformation, and market leadership through strategic alliances across R&D, tech, and supply chains.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")